Swedish Orphan Biovitrum AB Aktie
| 27,28EUR | -0,36EUR | -1,30% |
WKN DE: A0LA5K / ISIN: SE0000872095
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 50,29 |
| Investor AB (Investment Company) | 34,54 |
| AstraZeneca PLC | 9,84 |
| Fjärde AP-fonden | 5,90 |
| Fjarde AP Fonden | 5,90 |
| Swedish Orphan Biovitrum AB | 4,10 |
| Handelsbanken Fonder AB | 2,19 |
| Polar Capital Funds Plc - Healthcare Opportunities Fund | 1,31 |
| Folksam | 1,02 |
| Artisan International Small-Mid Fund | 0,93 |
| AMF Aktiefond Sverige | 0,80 |
| Nordea Investment Management AB | 0,75 |
| SEB Investment Management AB | 0,73 |
| Vanguard Total International Stock Index Fund | 0,72 |
| Länsförsäkringar Fondförvaltning AB | 0,71 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 1 377 | 1 509 | 1 559 | 1 556 | 1 772 |
| Umsatz pro Mitarbeiter in Mio. EUR | 10,35 | 10,11 | 9,96 | 12,08 | 12,49 |
Bilanz (in Mio. SEK) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 7 323 | 8 168 | 8 778 | 11 211 | 12 671 |
| Summe Anlagevermögen | 38 471 | 40 347 | 39 883 | 41 285 | 61 356 |
| Summe Aktiva | 45 794 | 48 515 | 48 661 | 52 496 | 74 027 |
Bilanz (in Mio. SEK) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 28 864 | 28 309 | 25 458 | 25 971 | 40 160 |
| Summe Eigenkapital | 16 930 | 20 206 | 23 203 | 26 525 | 33 867 |
| Summe Passiva | 45 794 | 48 515 | 48 661 | 52 496 | 74 027 |
Adresse
| Tomtebodavägen 23A, 112 76 Solna | |
| Telefon | +46 (8) 697-20-00 |
| Fax | +46 (8) 697-23-30 |
| Internet | http://www.sobi.com |
Management
|
Annette V. Clancy
Independent Director |
|
Armin Reininger
Head-Medical & Scientific Affairs |
|
Christine Wesström
Head-Technical Operations |
|
Christophe Bourdon
Director |
|
Daniel Rankin
Head-Strategy & Corporate Development |
|
David D. Meek
Chairman |
|
Filippa Stenberg
Independent Director |
|
Gerard Tobin
Head-Investor Relations |
|
Guido Oelkers
President & Chief Executive Officer |
|
Helena Ildiko Saxon
Independent Director |
|
Henrik Stenqvist
Chief Financial Officer |
|
Katy Mazibuko
Director |
|
Lena Bjurner
Head-Human Resources |
|
Lydia Abad-Franch
Chief Medical Officer, Head-Research & Development |
|
Mahmood Ladha
Head-Strategic Transformation Operations |
|
Mats Lek
Director |
|
Norbert Oppitz
Head-International |
|
Pablo de Mora
Head-Global Marketing & Access |
|
Per Richard Torbjörn Hallberg
General Counsel & Head-Legal Affairs |
|
Staffan Schüberg
Independent Director |
|
Sven Anders Ullman
Director |
|
Zlatko Rihter
Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
